Veru CEO Steiner joins Canaccord Genuity Growth Investors Conference fireside chatPUBT·Jul 30 at 07:33 AMVERU+0.90%
Cross-Sector M&A Accelerates as U.S. Mid-Caps Push for RestructuringGlobal Report·Jul 28 at 04:12 AMFXHO-12.13%FNVTF
Veru completes Phase 2b PLATEAU trial enrolling 250 patients for weight loss with Enobosarm and Semaglutide combo.Unusual Whales·Jul 27 at 07:12 AMVERU+0.90%
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | VERU Stock NewsStockTitan·Jul 26 at 11:10 PMVERU+0.90%
Veru says press release available on 2026 Obesity & Weight Loss Drug Development Summit presentationPUBT·Jul 7 at 07:36 AMVERU+0.90%
Veru enters at-the-market equity sales agreement for up to $21.8 million stock offeringPUBT·Jul 2 at 03:09 PMVERU+0.90%
Pre-market hot trades in US stocks: Aptorum up 14.85% pre-market; Veru down 14.41% pre-marketPrice Alert·Jun 8 at 04:12 AMAPM0.00%VERU+0.90%
Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA...rttnews·Jun 4 at 09:45 PMHCAT+0.48%ALVO+15.41%
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·Jun 4 at 12:06 PMAIM+7.91%ADTX0.00%
Veru sharews are trading higher after the company announced it entered into a clinical supply agreement with Novo Nordisk to evaluate the combination of Enobosarm with Wegovy.benzinga_article·Jun 4 at 11:16 AMVERU+0.90%NVO-8.78%
